Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 132Observational 5Expanded_access 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Hodgkin Disease 1Hematologic Diseases 1

Interventions

venetoclax 3fludarabine phosphate 3fludarabine 3navitoclax 2ibrutinib 2brexucabtagene autoleucel 2axicabtagene ciloleucel 2asparaginase erwinia chrysanthemi recombinant 2Cyclophosphamide 2zanubrutinib 1tisagenlecleucel 1tipifarnib 1tafasitamab 1sugemalimab 1selinexor 1plerixafor 1pirtobrutinib 1nilotinib 1midostaurin 1loncastuximab tesirine 1idelalisib 1glucarpidase 1eryaspase 1ceritinib 1Whole-Body Irradiation 1Tacrolimus 1Rituximab 1Proton Pump Inhibitors 1Mycophenolic Acid 1Hydrocortisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Brentuximab Vedotin × Lymphoid × Clear all
NCT01196208 2020-09-21

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Seagen Inc.

No longer available
DermatologicLymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡